News on PCOS
December 2006
in “
Annales D Endocrinologie
”
TLDR Estrogen-progestin contraception lowers ovarian, endometrial, and colon cancer risk but may raise breast and cervical cancer risk, helps with menstrual and acne issues, and new methods are as effective as pills. Metformin helps overweight women with PCOS and insulin resistance, and dopamine agonists treat prolactinomas.
The document from 2006 discusses contraception, polycystic ovary syndrome (PCOS), and prolactinomas. It notes that combined estrogen-progestin contraception reduces the risk of ovarian, endometrial, and colon cancer but may slightly increase breast cancer risk in very young women and moderately increase cervical cancer risk. Benefits of this contraception include protection against pregnancy complications, menstrual disorder improvement, and acne treatment. New contraceptive methods like transdermal patches and vaginal rings are as effective as oral contraceptives, while progestin-only options and intrauterine devices with levonorgestrel are also available. Emergency contraception has been simplified to a single levonorgestrel dose. Research continues on contraceptive vaccines and male contraception. PCOS, a leading cause of anovulation and infertility, is treated based on various patient needs, with metformin being beneficial for overweight women with insulin resistance. For prolactinomas, dopamine agonists like cabergoline are preferred, with specific management for women desiring pregnancy. The document does not include specific study numbers or detailed results.